(Boursier.com) — Adocia is the star of the day on the Parisian market with a title that soars by more than 20% to 3.99 euros. The biotech unveiled positive new data in its phase 2 study evaluating M1Pram, its co-formulation combining M1 insulin and pramlintide in a standard insulin pen, in patients with type 1 diabetes. Adocia speaks even “exceptional results” in obese people with this type of diabetes.
For Oddo BHF, these new data, which confirm the first positive results of the phase 2 study communicated last June, support the interest of its effectiveness, particularly in type 1 diabetic patients suffering from overweight or obesity. The broker recalls that Adocia is currently exploring avenues of partnerships for the further development of M1Pram. These new data should arouse even more the interest of potential partners, according to the broker, ‘neutral’ on the value.
©2022 Boursier.com